“…The incidence rate of PPM implantation within 30 days after TAVR in our institution (8.4%) is comparable to that reported by the PARTNER 1, 2, and 3 trials that used balloon‐expandable valves (6.6%‐8.8%) 3,5,7 . It is lower however than a lot of recently reported single institutional experiences that used both self‐expanding and balloon expandable valves (incidence rates between 11% and 28%) 10,11,13,14,16,17 . These interinstitutional differences may be partly explained by our higher use of balloon‐expandable valves (77%) which are generally associated with a lower risk of PPM implantation due to their higher level of implantation, 18 as well as our use of newer generation self‐expanding Evolut valves rather than first generation CoreValves which have a lower risk of PPM implantation 19 .…”